Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
Total Valuation
Immuneering has a market cap or net worth of $56.50M. The enterprise value is ―.
Market Cap$56.50M
Enterprise Value―
Share Statistics
Immuneering has 35,985,703 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding35,985,703
Owned by Insiders16.35%
Owned by Institutions1.06%
Financial Efficiency
Immuneering’s return on equity (ROE) is -1.47 and return on invested capital (ROIC) is -140664.53%.
Return on Equity (ROE)-1.47
Return on Assets (ROA)-1.16K
Return on Invested Capital (ROIC)-140664.53%
Return on Capital Employed (ROCE)-1.42K
Revenue Per Employee0.00
Profits Per Employee-1.13M
Employee Count54
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immuneering is >-0.01. Immuneering’s PEG ratio is >-0.01.
PE Ratio>-0.01
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio>-0.01
Income Statement
In the last 12 months, Immuneering had revenue of 0.00 and earned -61.04B in profits. Earnings per share was -2.04K.
Revenue0.00
Gross Profit0.00
Operating Income-64.07B
Pretax Income-61.04B
Net Income-61.04B
EBITDA-60.32M
Earnings Per Share (EPS)-2.04K
Cash Flow
In the last 12 months, operating cash flow was -14.12B and capital expenditures -8.99M, giving a free cash flow of -14.13B billion.
Operating Cash Flow-14.12B
Free Cash Flow-14.13B
Free Cash Flow per Share-392.63
Dividends & Yields
Immuneering pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.44
52-Week Price Change4.23%
50-Day Moving Average1.42
200-Day Moving Average1.77
Relative Strength Index (RSI)55.06
Average Volume (3m)211.44K
Important Dates
Immuneering upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 5, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Immuneering as a current ratio of 5.28, with Debt / Equity ratio of 9.76%
Current Ratio5.28
Quick Ratio5.28
Debt to Market Cap0.00
Net Debt to EBITDA530.18
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immuneering has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Immuneering EV to EBITDA ratio is 529.08, with an EV/FCF ratio of 579.40.
EV to Sales0.00
EV to EBITDA529.08
EV to Free Cash Flow579.40
EV to Operating Cash Flow580.29
Balance Sheet
Immuneering has $35.87B in cash and marketable securities with $4.08B in debt, giving a net cash position of -$31.78B billion.
Cash & Marketable Securities$35.87B
Total Debt$4.08B
Net Cash-$31.78B
Net Cash Per Share-$883.21
Tangible Book Value Per Share$1.15
Margins
Gross margin is 25.84%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin25.84%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immuneering is $15.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.00
Price Target Upside913.51% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-7.78%